Related Experiment Video
Updated: Aug 11, 2026
07:02
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Summary
Oral meptazinol offers effective pain relief for mild to moderate pain, comparable in potency to other analgesics. While nausea is a common side effect, it presents a viable option for pain management.
Area of Science:
- Pharmacology
- Pain Management
Background:
- An oral formulation of meptazinol has been developed and is available in the United Kingdom.
- Meptazinol's potency is comparable to established analgesics like dextropropoxyphene/paracetamol and pentazocine.
Purpose of the Study:
- To evaluate the efficacy and side effect profile of an oral meptazinol formulation.
- To determine the suitability of oral meptazinol for different pain severities.
Main Methods:
- Clinical evaluation of oral meptazinol formulation.
- Comparative analysis of meptazinol's potency against dextropropoxyphene/paracetamol and pentazocine.
Main Results:
- Oral meptazinol (200 mg) demonstrates comparable analgesic potency to dextropropoxyphene 32.5 mg/paracetamol 325 mg or pentazocine 50 mg.
- Nausea is identified as the primary adverse effect; constipation and dysphoria are minimal.
- Variable first-pass metabolism may limit its use in severe pain conditions.
Conclusions:
- Oral meptazinol is effective for managing mild to moderate pain.
- The side effect profile, particularly the low incidence of constipation and dysphoria, is favorable.
- Its utility in severe pain is constrained by first-pass metabolism, but it remains a valuable option for less severe pain.
